Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
17p below placing price - yet another opportunity to top up for those who appreciate the risk/reward setup here. Pound cost averaging the way to go.
Another gift entry/top up price based on risk/reward. 17p below placing price on no negative news.
Keep on posting Wyn and ignore those who have no interest in or are challenged by TA. They don't need to read what you have to say but some of us welcome your thoughts and weigh what you post with other opinions and our own views. Failing to trade a volatile share like this one is a missed opportunity to get ones average price down while we wait for the company to prove the science. Most have bought in at much higher prices expecting the success of the LFT. Volatility now provides opportunity to mitigate risk.
If you check the record, NDN was suggesting cautious purchases i.e. pound cost averaging when the SP fell below (from memory) about 75p. This concurred with my own thoughts at the time and my recent average is 57p. From my perspective I read this board to obtain a broad range of views and technical information and make decisions about trading the stock accordingly. I considered the risk/reward of anything 20% or more under the 120p placing price to be extremely attractive and still do, given the IP and the substantial potential upside of a buyout at some point in the future.
Get well soon Timster.
This has been a spectacular recent rise but we are still only at the placing price. Most LTHs are still underwater. The change in sentiment is welcome but Wyn is right. This still has massive upside potential but that's all, at present. I topped up in tranches between 40p and 75p, as suggested by another despised poster on here and have sold a few as risk mitigation today. Nothing goes up in a straight line so a small retrace will be a good top up/entry point if you believe in the overall potential, as I do. What a great opportunity to back a small British biotech that could revolutionise cancer care. GLA
@travel_light. Good point and now that they have to be paid for, companies should want the most accurate and reliable test there is. As to the shareholders (aka owners) being advised where we are at with Affidx - well good luck with that one!
Thursday RNS anyone? Could catch a few with their shorts down?
I thought it was BHP and JLP didn't fancy a David v Goliath confrontation. I think that you'll find it was quietly dropped as a fight would have distracted from other projects considered more lucrative at the time.
If Avacta were to sell off the Diagnostics division could an acquirer gain the benefit of the Affimer IP or is this exclusive to Avacta? Is this what you were alluding to Ophidian i.e. that Avacta doesn't actually own the IP so couldn't necessarily pass on the benefit upon a sale?
@Wiggly I would say that such a strategy would be preferable to another placing at a deeply discounted price.
@Wyndrum. "the non movement of the SP suggests this news might have been leaked out over the last couple of days and thats where the recent rise has come from".
Are you suggesting that a rise of 40%, in just over a week, is down to the leak of this relatively inconsequential piece of news?
Very good news and makes the other JV with Jubilee more likely to proceed (IMO). Hope the fact that Colin Bird is standing down as chairman of Jubilee soon isn't seen as a negative. I assume the relationship he has with LC at JLP hasn't been affected by him standing down.
So they've dropped the section about the commercialisation of the LFT in Q1 altogether then.
What we need is a reliable LFT that picks up the BA-2 variant of Omicron.
https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Finews.co.uk%2Fnews%2Fcovid-hospital-admissions-rise-mixing-waning-immunity-push-up-cases-1512721&data=04%7C01%7C%7Cca94a9c154824b9f7aec08da058d5b52%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C637828401912645111%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=yhelr4oQT%2BAqgruNA0ldluSPAaR%2Fi8Z2Z%2BaP4fF%2FjUs%3D&reserved=0
As far as I am aware the company has never given an update as promised in the RNS below. Deepverge was previously called Integumen.
Thu, 24th Sep 2020 07:00
RNS Number : 9402Z
Avacta Group PLC
24 September 2020
24 September 2020
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Update on Integumen Collaboration
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to note the update by Integumen plc (AIM: SKIN) ("Integumen") provided today regarding their ongoing development of Affimer-based sensors for the coronavirus in waste water and in human breath.
Dr Alastair Smith, Chief Executive of Avacta Group commented:
"I am very pleased to learn of the promising evaluation of the Affimer reagents in Integumen's sensor systems. Once detailed validation of the sensors has been carried out using SARS-COV-2 virus samples at the University of Aberdeen, and we have reviewed those data, Avacta will provide a further update to the market."
- Ends-
Interesting to see the impact of the closing of the short positions on the BooHoo share price (BOO). I personally think we'll see the same here and soon.
Get back in the ranks Fraser.
Mind you we could be now that Vlad can't get a Big Mac!
The point surely is that James Spicer is the link Wyn?
I think the lack of an RNS simply confirms the confidence in all that's going on behind the scenes. Management see no need to shore up the share price at this stage.
Good find. Encouraging endorsement for Affimer platform. Thanks for sharing.